University of Michigan
Cereno signs license agreement with University of Michigan
Cereno Scientific reports continued progress in the company's plan to take two preclinical candidates for the treatment of cardiovascular diseases to clinical...
Cereno Scientific summarizes Q3
The reporting season is in full swing and during the day...
Cereno Scientific raises SEK 61 million through the exercise of warrants
Cereno's shareholders strongly believe in the company's portfolio of...
BioStock Studio: Cereno Scientific summarizes the first quarter of the year
Sten R Sorensen
Cereno Scientific's CS014 attracts interest within the medical community
Cereno Scientific's pharmaceutical portfolio continues to attract attention within...
Cereno Scientific presents promising CS585 data
Cereno Scientific's records for the preclinical drug candidate CS585...
Cereno Scientific faces an eventful 2022
2021 brought significant progress for Cereno Scientific. The company...
Cereno Scientific receives SEK 95,3 million
Cereno Scientific recently achieved an important milestone when...
Cereno Scientific expands patent portfolio
Cereno Scientific's patent portfolio continues to grow. This week...
Status report Cereno Scientific – Expanded potential in cardiovascular disease
Cardiovascular diseases are the leading cause of death worldwide and...
Cereno Scientific is driving a paradigm shift in CVD
Cardiovascular disease claims more victims than any other...
Cereno Scientific expands collaboration with University of Michigan
Last week, Cereno Scientific announced that it had added...